Post updated: A reader (HT: RK) emailed in suggesting that the two funds (ICMYX and ETGLX) are not correctly characterized by Morningstar since they both hold lots of cash and bonds – which even further validates my point – the Tiger Cubs portfolio would be the #1 performing mutual fund YTD. So, my apologies – there are zero diversified equity funds up on the year.
—-
Did you know that out of the 9000 stock mutual funds in Morningstar‘s database there are only two ZERO funds up on the year?
The Tiger Cubs portfolio I mentioned at the end of 2008 is up 1.8% this year. That would be the 2nd best performing stock fund this year – out of 9000 funds. This fund is beating the market by 15% in 2009, and has averaged 15% outperformance a year since 2000.
For those new to my blog World Beta, this portfolio was generated using AlphaClone. You can take the tour here. The strategy simply takes the top 10 most popular stocks held by 20 hedge fund progeny of Julian Robertson’s Tiger Management. The free Tiger Clone portfolio is here.
The current portfolio is:
Qualcomm (QCOM)
Mastercard (MA)
Google (GOOG)
Transdigm (TDG)
Visa (V)
America Movil (AMX)
America Tower (AMT)
Philip Morris (PM)
Priceline (PCLN)
Covanta (CVA)
Disclosure: Long GOOG, TDG, AMX, PCLN, and MA.
[...] reader (HT: RK) emailed in suggesting that the two funds (ICMYX and ETGLX) from my Tiger Cubs post are not correctly characterized by Morningstar since they both hold lots of cash and bonds – [...]
ETGLX: who are they? Should we buy? read below
Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it
February 23, 2009
SRI Fund is Category King for January 2009
by Robert Kropp
Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal
SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.
During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.
The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.
The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.
Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.
Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.
Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it
February 23, 2009
SRI Fund is Category King for January 2009
by Robert Kropp
Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal
SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.
During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.
The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.
The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.
Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.
Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.
ETGLX: who are they? Should we buy? read below
Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it
February 23, 2009
SRI Fund is Category King for January 2009
by Robert Kropp
Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal
SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.
During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.
The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.
The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.
Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.
Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.
Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it
February 23, 2009
SRI Fund is Category King for January 2009
by Robert Kropp
Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal
SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.
During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.
The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.
The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.
Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.
Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.